Elekta AB (SE:EKTA.B)
:EKTA.B
Top Page
Elekta AB
(EKTA.B)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr56.00
▼(-1.67% Downside)
Action:ReiteratedDate:03/07/26
The score is held back primarily by deteriorating profitability (TTM net loss and margin compression) and increased leverage, with valuation also pressured by an extremely high P/E. These negatives are partly balanced by strong free cash flow generation and supportive technicals with the share price trending above key moving averages.
Positive Factors
Strong operating & free cash flow
Despite reported earnings weakness, Elekta converts sales into cash reliably, producing roughly SEK 2.0B of free cash flow TTM. Durable cash generation supports service operations, working capital and selective reinvestment, giving the company financial ballast while earnings recover.
Negative Factors
Margin compression and net loss
Recent margin deterioration and a TTM net loss signal impaired profitability from either cost pressure, adverse mix or non-operating items. Weaker margins reduce retained earnings and ROE, constrain reinvestment capacity, and increase reliance on cash reserves or financing until structural cost or revenue improvements occur.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong operating & free cash flow
Despite reported earnings weakness, Elekta converts sales into cash reliably, producing roughly SEK 2.0B of free cash flow TTM. Durable cash generation supports service operations, working capital and selective reinvestment, giving the company financial ballast while earnings recover.
Read all positive factors
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr20.80B
Dividend Yield4.25%
Average Volume (3M)1.33M
Price to Earnings (P/E)546.4
Beta (1Y)1.05
Revenue Growth-0.90%
EPS Growth-70.95%
CountrySE
Employees4,541
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.88
Shares Outstanding368,587,650
10 Day Avg. Volume896,136
30 Day Avg. Volume1,329,676
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)2.13
Price to Sales (P/S)1.04
P/FCF Ratio17.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr52.50Price Target Upside-7.81% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)3.29
Revenue Forecast (FY)kr16.91B
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear ...
How the Company Makes Money
Elekta makes money mainly by selling and supporting radiation therapy and related software solutions to healthcare providers. Key revenue streams typically include: (1) Hardware/system sales: revenue from delivering radiation therapy systems and o...
Elekta AB Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
52
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.11B | 18.02B | 18.12B | 16.87B | 14.55B | 13.76B |
| Gross Profit | 6.42B | 6.75B | 6.80B | 6.35B | 5.44B | 5.61B |
| EBITDA | 1.80B | 2.19B | 3.29B | 2.57B | 2.69B | 3.07B |
| Net Income | -39.00M | 237.00M | 1.30B | 943.00M | 1.15B | 1.25B |
Balance Sheet | ||||||
| Total Assets | 27.68B | 28.98B | 31.41B | 29.61B | 26.30B | 24.84B |
| Cash, Cash Equivalents and Short-Term Investments | 2.54B | 2.96B | 2.78B | 3.27B | 3.07B | 4.40B |
| Total Debt | 7.28B | 7.57B | 7.25B | 6.67B | 5.70B | 6.24B |
| Total Liabilities | 19.67B | 20.13B | 20.63B | 19.88B | 17.39B | 16.65B |
| Stockholders Equity | 7.97B | 8.80B | 10.78B | 9.73B | 8.91B | 8.20B |
Cash Flow | ||||||
| Free Cash Flow | 2.00B | 1.06B | 817.00M | 400.00M | 450.00M | 1.71B |
| Operating Cash Flow | 2.65B | 2.63B | 2.46B | 1.96B | 1.86B | 2.55B |
| Investing Cash Flow | -1.15B | -1.67B | -1.92B | -1.61B | -1.65B | -613.00M |
| Financing Cash Flow | -2.29B | -607.00M | -1.10B | -129.00M | -1.73B | -3.60B |
Elekta AB Technical Analysis
Negative
56.95
Price Trends
56.01
Negative
54.33
Positive
50.45
Positive
Market Momentum
-0.37
Positive
45.00
Neutral
48.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 56.95 is above the 20-day moving average (MA) of 56.77, above the 50-day MA of 56.01, and above the 200-day MA of 50.45, indicating a neutral trend. The MACD of -0.37 indicates Positive momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 48.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr28.98B | 49.61 | 20.86% | ― | 39.37% | 189.04% | |
66 Neutral | kr6.66B | 34.29 | 24.30% | 1.32% | 10.48% | 25.19% | |
64 Neutral | kr7.16B | 31.86 | 15.16% | ― | 11.30% | -14.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | kr894.82M | 103.06 | 6.93% | ― | -5.80% | -65.99% | |
54 Neutral | kr20.80B | 546.38 | 3.08% | 4.25% | -0.90% | -70.95% | |
49 Neutral | kr12.56B | -3.70 | 3.34% | 0.80% | -1.29% | ― |
* General Sector Average
SE:EKTA.B
Elekta AB
54.45
10.63
24.26%
SE:VITR
Vitrolife AB
92.75
-57.24
-38.16%
SE:CAMX
Camurus AB
483.60
-36.40
-7.00%
SE:RAY.B
RaySearch Laboratories AB
194.20
-8.28
-4.09%
SE:CRAD.B
C-Rad AB Class B
26.50
0.15
0.57%
SE:MCAP
MedCap AB
475.00
136.50
40.32%
Elekta AB Corporate Events
Elekta absorbs heavy restructuring charge as margin initiatives start to bite
Mar 5, 2026
Elekta reported a mixed third quarter, with net sales up 2 percent in constant currencies but down 10 percent in SEK, as currency headwinds and tariffs weighed on reported results. The company maintained a strong book-to-bill ratio of 1.17, driven...
Elekta Adjusts Nomination Committee Ahead of 2026 Annual General Meeting
Feb 25, 2026
Elekta has announced a change in its Nomination Committee ahead of the Annual General Meeting scheduled for September 3, 2026, with Anna Magnusson replacing Thomas Wuolikainen as the Fourth Swedish National Pension Fund’s representative. Fol...
Elekta Schedules March 5 Call to Present Q3 2025/26 Results
Feb 19, 2026
Elekta has invited analysts and investors to a conference call and webcast on March 5 at 9:00 a.m. CET to present its third-quarter 2025/26 financial results, with the interim report scheduled for release earlier that morning. The session, led by ...
Elekta Unveils Cost-Cutting Overhaul and Growth Push in U.S. and China
Jan 30, 2026
Elekta has outlined a new strategic direction centered on growth, innovation and operational efficiency, anchored in a revamped operating model. As part of this transformation, the company will cut 450 jobs, targeting annual cost savings of more t...
Elekta Names Tomas Eliasson as Newly Created Vice Chair of the Board
Jan 23, 2026
Elekta has created a new position of Vice Chair of the Board and appointed current board member and Audit Committee chair Tomas Eliasson to the role, effective immediately. Eliasson, who joined the board in 2023, brings extensive experience in fin...
Elekta Wins FDA Clearance for AI-Enhanced Evo Linear Accelerator in U.S.
Jan 16, 2026
Elekta has received U.S. FDA 510(k) clearance for its Elekta Evo CT-Linac, enabling the company to begin marketing the advanced linear accelerator to radiation oncology providers in the United States. The system incorporates Elekta’s Iris hi...
Elekta Plans January 2026 Strategic Update on Growth and Innovation
Jan 12, 2026
Elekta will host a digital Strategic Update event on January 30, 2026, aimed at investors, analysts and other stakeholders, where President and CEO Jakob Just-Bomholt and the executive leadership team will outline the company’s strategic dir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.